Novo Nordisk Shares Signal Potential Turnaround After Steep Decline

A wave of cautious optimism is beginning to emerge for Danish pharmaceutical giant Novo Nordisk following a prolonged period of declining share performance. This shift in sentiment is being driven by two significant developments: an unexpected upgrade from a major analyst firm and the publication of groundbreaking clinical trial data. These events are prompting investors to question whether the company is positioned for a meaningful recovery.

Breakthrough Clinical Data for Oral Weight-Loss Drug

Coinciding with the improved analyst outlook, Novo Nordisk released highly promising results from its OASIS-4 trial in the New England Journal of Medicine. The study focused on an oral formulation of semaglutid (25 mg), demonstrating substantial efficacy:

• Participants experienced an average weight reduction of 13.6%, starkly contrasting with a 2.2% loss in the placebo group
• Nearly 30% of study subjects achieved a weight loss exceeding 20% of their total body mass
• The treatment’s safety profile proved consistent with the injectable version, Wegovy

This oral tablet could represent a pivotal advancement in the obesity treatment market, as it offers a preferred alternative for patients who are averse to injectable therapies.

Berenberg Issues Surprising Upgrade

In a notable vote of confidence, the German investment bank Berenberg revised its rating on Novo Nordisk shares upward from “Hold” to “Buy.” This upgrade arrives at a critical juncture as the market assesses the company’s recent strategic restructuring initiatives and an increasingly competitive landscape.

Major Restructuring Underway

The company is currently executing one of the most significant organizational overhauls in its history under the leadership of new CEO Mike Doustdar. The plan involves a reduction of 9,000 positions, equating to approximately 11.5% of its global workforce. The cuts are heavily concentrated in Denmark, which will account for 5,000 of the job losses. This restructuring is projected to yield annual savings of 8 billion DKK by 2026.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

However, these strategic benefits come with substantial near-term costs. The company anticipates incurring one-time charges of roughly 9 billion DKK in the third quarter of 2025 and has concurrently lowered its profit growth forecast for 2025 to a range of 4-10%.

Intense Competitive Pressures Persist

The drastic cost-cutting measures are a direct response to mounting competitive threats. Eli Lilly’s Zepbound continues to capture market share within the lucrative GLP-1 sector. Furthermore, the management team at Novo Nordisk has identified the U.S. trade in compounded imitation drugs as the single most significant factor eroding Wegovy’s market presence.

Year-to-date, the company’s equity has declined in value by approximately 46%, and it is now trading considerably below its historical valuation levels. Its current price-to-earnings (P/E) ratio of 13.56 sits beneath the industry average of 14.71 and remains far removed from its five-year average of 29.25.

Pipeline Holds Promise for Future Growth

Despite these immediate headwinds, Novo Nordisk’s development pipeline contains several promising opportunities. CagriSema, a combination therapy that has shown encouraging early results, is scheduled for regulatory submission in 2026. The company is also pursuing label expansions for its existing products, including investigating cardiovascular indications for Wegovy.

The central question for investors is whether the pharmaceutical leader can leverage its innovation pipeline and strategic restructuring to outpace the competition. While challenges remain, these recent developments provide a foundation for measured optimism regarding its long-term trajectory.